Literaturverzeichnis
zum Titelthema „Prävention in der Nephrologie. Was ist gesichert – was ist Mythos?“
Bayerisches Ärzteblatt 10/2014, Seite 520 ff.
von Dr. Oliver Sarkar, Universitätsprofessor Dr. Dr. h. c. Uwe Heemann und Professor Dr. Lutz Renders
1. Jones C, Roderick P, Harris S, et al:. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006 Aug;21(8):2133-43.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J. 2013;34:2159–2219.
3. Appel LJ, Wright, Jr JT, et al.: Intensive bloodpressure control in hypertensive chronic kidney disease. New Engl J Med 2010; 363: 918-929.
4. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139:244–252.
5. Messerli FH, Mancia G, Conti R, Hewkin AC, Kupfer S, Champion A, et al.: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Int Med 2006; 144: 884-893.
6. Verdecchia P, Staessen JA, Angeli F, de SG, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525–3.
7. McMahon EJ, Bauer JD, Hawley CM, et al.: A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013 Dec; 24 (12): 2096-103.
8. Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet.
DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3-10.
9. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
10. Rahman M, Pressel S, Davis BR, et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic:Areport from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:936-946.
11. Yusuf S, Sleight P, Pogue J, et al.. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145-53.
12. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:995-1003.
13. Melian EB, Jarvis B: Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 2002; 62:787-816.
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J:
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;
341:709-717.
15. Cicoira M, Zanolla L, Rossi A, et al.: Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002; 40:304-310.
16. Hill NR, Lasserson D, Thompson B, et al.: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials.
2014 May 8;15:160.
17. Bakris GL, Fonseca V, Katholi RE, et al: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:Arandomized controlled trial. JAMA 2004; 292:2227-2236.
18. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. Mar 2007;49(3):373-382.
19. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatinprevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. Jun 2004;4(6):988-995.
20. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. Jun 14 2003; 361(9374):2005-2016.
21. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. Dec 2005;16(12):3748-3754.
22. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. Jun 25 2011;
377(9784):2181-2192.
23. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. Nov 2009;
54(5): 810-819.
24. Geng Q, Ren J, Song J, et al., Meta-Analysis of the Effect of Statins on Renal Function. Am J Cardiol. 2014 Jun 6. pii: S0002-9149(14)01226-0.
25. Fried LF, Orchard TJ, Kasiske BL: The effect of lipid reduction on renal disease progression: A metaanalysis. Kidney Int 2001; 59:260-269.
26. Nakamura T, Sato E, Fujiwara N, et al., lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev. 2010 Sep-Oct;3(5):304-7.
27. Zhou S, Zhao P, Li Y, et al., Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism. Eur J Pharmacol. 2014 Jul 5;740C:9-14.
28. Johnson C, Waters DD, DeMicco DA, et al, Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol. 2008 Nov 15;102(10):1312-7.
29. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney 1990; Dis 15:458-482.
30. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;
61:1887-1893
31. Wanner C, Krane V, März W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238-48.
32 . Holdaas H, Holme I, Schmieder RE, et al; AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011 Jul;22(7):1335-41
33. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. Sep 30 1993; 329 (14): 977-986.
34. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. Apr 2000; 23 Suppl 2:B21-29.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, (UKPDS 33). Lancet. Sep 12 1998;352(9131): 837-853.
36. Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. Jul 27 2009;169(14):1307-1316.
37. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. Jun 12 2008;358(24):2560- 2572.
38. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect ofintensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. Aug 7 2010;376(9739):419-430.
39. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. Jan 8 2009;360(2):129-139.
40. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. Nov 28 2011;171(21):1920-1927.
41. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. Feb 2001; 24(2):382-391.
42. Shikata K, Haneda M, Koya D, et al.: DNETT-Japan Study Group. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan):
Rationale and study design. Diabetes Res Clin Pract. 2010 Feb;87(2):228-32.
43. Gohda T, Niewczas MA, Ficociello LH, et al.: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012 Mar; 23(3):516-24.
44. The EUCLID Study Group; Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997 Jun 21;349 (9068):1787- 92.
45. Haller H, Ito S, Izzo JL Jr, et al. ; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 Mar 10;364(10):907-17.
46. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
47. Gaede P, Hansen HP, Parving HH, Pedersen O: Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant 18:539-542, 2003
48. Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 2001; 18:756-760.
49. Troyanov S, Wall CA, Miller JA, et al., Toronto Glomerulonephritis Registry Group:
Idiopathic membranous nephropathy: definition and relevance of a partial remission.
Kidney Int. 2004;66(3):1199.
50. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
51. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
52. Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet.
2008 Aug 16; 372(9638): 547-53.
53. Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23): 2204-13.
54. Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 2000; 14:295-301.
55. Li L, Yang C, Zhao Y, et al.; Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014 Jul 27;15(1):122.
56 Kamei K, Konta T, Hirayama A, et al.: A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014 Jul 24. pii: gfu256.
57 Obermayr RP, Temml C, Gutjahr G, et al.: Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008 Dec;19(12):2407-13.
58. Testa A, Mallamaci E, Spoto B, et al.: Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clin J Am Soc Nephrol. 2014 Jun 6; 9(6): 1059-65.
59. Whelton A, MacDonald PA, Chefo S, et al.: Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013 Jan;125(1):106- 14.
60. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A metaanalysis. Ann Intern Med 124:627-632, 1996
61. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62:220-228, 2002
62. Meyer TW, Anderson S, Rennke HG, et al., Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int. 1987;31(3):752.
63. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;
31:954- 961.
64. Fukui M, Nakamura T, Ebihara I, et al., Low-protein diet attenuates increased gene expression of platelet-derived growth factor and transforming growth factor-beta in experimental glomerular sclerosis. J Lab Clin Med. 1993;121(2):224.
65. Kopple JD, Levey AS, Greene T, et al., ct of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;52(3):778.
67. Slomowitz LA, Monteon FJ, Grosvenor M, et al.: Effect of energy intake on nutritional status in maintenance hemodialysis patients. Kidney Int 1989; 35:704-711.
68. Ikizler TA, Greene JH, Yenicesu M, Schulman G, Wingard RL, Hakim RM: Nitrogen balance in hospitalized chronic hemodialysis patients. Kidney Int Suppl 1996; 57:S53- S56.
69. Walser M, Hill S, Tomalis EA, ment of nephrotic adults with a supplemented, very low- protein diet. Am J Kidney Dis. 1996;28(3):354.
70. Menon V, Kopple JD, Wang X, et al; Effect of a very low-protein diet on outcomes:
long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2009;53(2):208.
71. Chidester JC, Spangler AA, Fluid intake in the Institutionalized Elderly, J Am Diet Assoc. 1997 Jan;97(1):23-8
72. Hebert LA, Greene T, Levey A, et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis. 2003 May;41(5):962-71.
73. Palmer SC, Wong G, Iff S, et al.: Fluid intake and all-cause mortality, cardiovascular mortality and kidney function: a population-based longitudinal cohort study. Nephrol Dial Transplant. 2014 Jul;29(7):1377-84.
